
08 Aug PAOLO RIZZARDI, MD
Paolo Rizzardi, MD, combines a strong scientific background with managerial skills gained in substantially contributing to successfully develop biotechnology companies and to achieve the market approval of advanced therapy medicinal products in the cell&gene therapy and oncology field. After spending more than 10 years in academia in Italy, UK, and Switzerland in developing programs for innovative immune-based/vaccination strategies in patients with HIV/AIDS, he has worked for more than 25 years in the cell&gene therapy biotech sector, developing a unique expertise in R&D, CMC, clinical and business development, development, engineering, and IP from target validation to market approval. He is co-Founder of AurorA-TT (www.aurora-tt.com) and Altheia Science (www.altheiascience.com).
He published over 90 peer-reviewed manuscripts and textbook chapters (6500+ citations, h-index 38), including seminal contribution to the field of gene therapy and HIV infection.

Sorry, the comment form is closed at this time.